REMS Safety Update on BLINCYTO®

May 25, 2021

ASCO has been notified of a recent safety notice relating to the drug BLINCYTO® (blinatumomab) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program. A REMS Letter for Professional Societies has been released to address the potential risks for (1) cytokine release syndrome (CRS), which may be life-threatening or fatal, (2) neurological toxicities, which may be severe, life-threatening, or fatal, and (3) preparation and administration errors associated with use of BLINCYTO®. More information for healthcare providers can be found on the BLINCYTO® REMS website for healthcare professionals.

Bookmark ASCO in Action for future notifications, as well as news, advocacy, and analysis on cancer policy.